
(MedPage Today) — ORLANDO — Postmenopausal women using hormone therapy (HT) saw significantly greater weight loss while taking the dual GIP/GLP-1 receptor agonist tirzepatide than their counterparts not using HT, according to a retrospective…
Source link : https://www.medpagetoday.com/meetingcoverage/tms/118146
Author :
Publish date : 2025-10-26 19:20:00
Copyright for syndicated content belongs to the linked
Source.